RE:RE:Entry here is still stupid cheap. Who said we were risk free HT? When the FDA told Telesta to submit with their current data set (extremely rare for FDA to do this) for final BLA submission (avoiding a costly 2nd FDA phase 3b trial) in my opinion took a lot of risk off the table. 50% of phase 3 trial drugs receive approval. Here's why I think we are much higher than that threshold. We have no safety issues (1.5% of patients experienced mild to moderate side effects) yet extremely efficatious, our only real competition is Cystectomy (bladder removal), an FDA panel member cited Urocidin / MCNA as a perfect candidate for much needed cancer treatment, current Firstline treatment (BCG) is so toxic Oncologist will do anything to avoid using it. So yes there still is some risk, however I like our chances and so do the new buyers the last few days it seems. We should be trading well over a dollar. as the SA article states https://seekingalpha.com/instablog/13833412-sujan-lahiri/3273535-bioniche-a-home-run-buying-opportunity-in-biotech -we have a higher than 80% chance of FDA approval. FDA approval should take us up to near a Billion market cap. GLA Beech